TOT Biopharm/Kexing Biopharm’s Biosimilar Bevacizumab Approved in Pakistan

On 1 July 2025, Kexing Biopharm announced via LinkedIn that Pakistan’s Drug Regulatory Authority has granted marketing approval to Arketin™, biosimilar to Roche/Genetech’s Avastin® (bevacizumab).

Arketin™ (marketed as Pusintin® in other regions) was developed by TOT BIOPHARM and is subject to an exclusive commercialisation agreement entered into with Kexing Biopharm in January 2022.  Pusintin® was approved in China in December 2021.